- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/12 - AntiepilepticsAnticonvulsants for grand-mal
Patent holdings for IPC class A61P 25/12
Total number of patents in this class: 36
10-year publication summary
|
1
|
0
|
1
|
0
|
3
|
3
|
7
|
4
|
5
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| GW Research Limited | 193 |
5 |
| Stoke Therapeutics, Inc. | 64 |
4 |
| Jazz Pharmaceuticals Research UK Limited | 218 |
4 |
| Cellixbio Private Limited | 155 |
2 |
| Indivior UK Limited | 194 |
2 |
| Katholieke Universiteit Leuven | 1194 |
2 |
| Shackelford Pharma Inc. | 9 |
2 |
| The Regents of the University of California | 19961 |
1 |
| Glaxosmithkline Intellectual Property (no.2) Limited | 287 |
1 |
| 23andMe, Inc. | 282 |
1 |
| Biolink Life Sciences, Inc. | 19 |
1 |
| BodyBio, Inc. | 28 |
1 |
| Izun Pharmaceuticals Corporation | 24 |
1 |
| Jawaharlal Nehru Centre for Advanced Scientific Research | 87 |
1 |
| Sage Therapeutics, Inc. | 364 |
1 |
| The University of British Columbia | 1495 |
1 |
| Xenon Pharmaceuticals Inc. | 189 |
1 |
| Zynerba Pharmaceuticals, Inc. | 48 |
1 |
| Sumitomo Pharma Co., Ltd. | 605 |
1 |
| RABINOWITZ, Stephen S. | 4 |
1 |
| Other owners | 2 |